http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Ming-lung Yu ),( Chao-hung Hung ),( Yi-hsiang Huang ),( Cheng-yuan Peng ),( Chun-yen Lin ),( Pin-nan Cheng ),( Rong-nan Chien ),( Shih-jer Hsu ),( Chen-hua Liu ),( Jee-fu Huang ),( Chung-feng Huang 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: The current study aims to elucidate the treatment efficacy (defined as undetectable HCV RNA throughout 12 weeks of post-treatment follow-up, SVR12) and safety DCV/ASV plus ribavirin for 12 weeks in HCV-1b patients without NS5A RAS. Methods: This is a single-arm, open-label phase 2 study. Seventy directly acting antivirals (DAA)-naïve HCV-1b patients without L31/Y93 RAS are planned to receive daclatasvir (60 mg/ day) and asunaprevir (100 mg twice daily) plus weight-based ribavirin (1000-1200 mg/day) for 12 weeks. After treatment they were followed up for 12 weeks. Results: As of 31 Oct 2017, 58 eligible patients are allocated to treatment, with a mean age of 59.3 years and female predominance (67.2%, 39/58). The mean HCV RNA was 5.87+0.77 log10 IU/mL; 23 patients (39.7 %) had significant hepatic fibrosis (>F2). In the modified intention-to-treat analysis, the rate of undetectable HCV at week 1, week 2, week 4, week 8 and endof- treatment was 25 % (14/56), 84.8 % (39/46), 100 % (46/46), 100 % (38/38) and 100 % (27/27), respectively. Undetectable HCV RNA were observed in all of the patients with HCV RNA assessable 4 weeks (SVR4, 18/18) and 12 weeks (SVR12, 12/12) post treatment. None of the 18 patients who completed the 12-week treatment experienced relapse during post-treatment follow-up. The most common adverse event was fatigue (78.3 %), followed by pruritus (65.2 %) and dizziness (52.2 %), of which were considered as ribavirin related. None of the participating subjects withdrew treatment or follow-up throughout the trial peroid. Three serious adverse events were reported which included urosepsis, appendicitis and left ureteral stone. All were unrelated to the investigating drugs. Conclusions: 12 weeks of DCV/ASV plus ribavirin was highly effective and safe in HCV-1b patients without NS5A RAS in the interim analysis. The satisfactory results would be anticipated in the full patient set.
Multidisciplinary Perspectives in Understanding Slow-moving Landslide
( Wei-an Chao ),( Ming-chien Chung ),( Keng-hao Kang ),( Chih-pin Lin ),( Tung-lin Tai ),( Hao-wen Yang ) 대한지질공학회 2019 대한지질공학회 학술발표회논문집 Vol.2019 No.2
Landslides have caused extensive infrastructure damage and threatened the human fatalities through the centuries. Among all triggered factors, massive precipitation and large earthquakes are considered to be the two key activators for pushing landslide moving, particularly for catastrophic landslides. The most acceptable mechanism resulting the landslide movement is liquefaction due to increasing water pore pressure. In this study, a landslide site has been well understood by hydrological, geophysical, geological, geodetic, geotechnical and seismological (H4GS) perspectives. Our seismic monitoring of daily relative velocity changes (dv/v) in sliding material decreased coinciding with first-half rainy period yet increased observing in post-half raining event. Geodetic survey (real-time kinematic, RTK; total station) before and after rainy period presents the vertical subsidence without any horizontal movement. The results from multidisciplinary investigation allow us to draw the conceptual model of landslide healing process caused by the water loading. Under the stability condition (F > 1.0) for each sliding materials, unconsolidated landslide colluvium and impermeable sliding surface could trap the seepage water to be as water pool, provided compact force acting on the materials below the sliding boundary. The vertical force of compaction facilitates to increasing the cohesion and strength of materials, tending the landslide material to be much stability. We demonstrated that healing process is periodically occurred but only for prolonged and intense precipitation combined with stability condition.